Qanatpharma AG (QP), Zuse Institute Berlin (ZIB), Enamine Ltd. and Proteros biostructures GmbH have announced the launch of a research collaboration to accelerate the discovery of novel therapeutics targeting cerebral perfusion deficits associated with subarachnoid hemorrhage (SAH).
Proteros Biostructures GmbH has established a new collaboration with Orion Corp. The two companies are engaging in a joint multitarget collaboration for early-stage drug discovery projects in oncology and pain using Proteros’ discovery platform, and now have decided to combine their expertise to assemble a chemically diverse small-molecule library collection. The nonexclusive agreement enables Proteros to exclusively offer access to this high throughput screening (HTS) library to all its clients.
Astrazeneca plc has signed up for more of the heavy-duty structure-based drug discovery services Proteros Biostructures GmbH specializes in, inking an extension to their existing collaboration agreement.
